China Resources Pharma's China Pharmaceutical Research Innovative Drug NIP003 Tablets Obtained Clinical Approval

On March 9, according to the official WeChat news of the China Pharmaceutical Research Institute, recently, NIP003 tablets, a new generation anticoagulant of the China Pharmaceutical Research Institute, a subsidiary of China Resources Pharma, obtained the "Notice of Drug Clinical Trial Approval" issued by the NMPA, and was approved for clinical use in the prevention of arteriovenous thrombosis.

NIP003 is a novel FXIa inhibitor with global intellectual property rights

In recent years, the incidence of cardiovascular and cerebrovascular diseases has been increasing year by year, and its high disability rate and high death rate pose a serious threat to people's health and bring a heavy burden to the society

Preclinical research data show that NIP003 has potent inhibitory activity against FXIa, and through structure-based molecular design, compared with the same target drug Milvexian, the off-target effect on plasma bradykininase and other targets is significantly improved.

Reference source: Financial Associated Press, China Resources Pharma official website